NCT02607670 is a Phase 2 clinical trial of TAT4 Gel in Nasolabial Folds, sponsored by Topokine Therapeutics, Inc..

Who is sponsoring NCT02607670?

NCT02607670 is sponsored by Topokine Therapeutics, Inc..

What drugs are being tested in NCT02607670?

Interventions in NCT02607670: TAT4 Gel, Matching placebo.

What condition does NCT02607670 study?

NCT02607670 studies Nasolabial Folds.

Is NCT02607670 still recruiting?

NCT02607670 is currently status unknown. Last updated 2 January 2016.

Last reviewed 2016-01-02 · How we verify

NCT02607670

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Phase 2, Randomized, Double-blind, Placebo-controlled Study of TAT4 Gel for the Reduction of Nasolabial Folds

Status unknown Phase 2 Last updated 2 January 2016

What this trial tests

Phase 2 trial testing TAT4 Gel in Nasolabial Folds in 111 participants. Status unknown.

Timeline

1 January 2016

Primary endpoint
1 August 2016

1 September 2016

Quick facts

Lead sponsor	Topokine Therapeutics, Inc.
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	treatment
Enrollment	111
Start date	1 January 2016
Primary completion	1 August 2016
Estimated completion	1 September 2016
Sites	1 location across United States

Drugs / interventions tested

TAT4 Gel — full drug profile →
Matching placebo — full drug profile →

Conditions studied

Nasolabial Folds — all drugs for Nasolabial Folds →

Sponsor

Topokine Therapeutics, Inc. — full company profile →

Who can join

Adults 35 to 60, any sex, with Nasolabial Folds. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Nasolabial Fold Severity Scale (Clinician-Reported)
Time frame: Day 91

Sponsor's own description

This is a Phase 2, randomized, double-blind, placebo-controlled study of TAT4 Gel for the reduction of moderate to severe nasolabial folds.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Topokine Therapeutics, Inc. trials

Trials by the same sponsor.

NCT02607683 — Phase 2b/3 Study of XAF5 Ointment for Steatoblepharon (Undereye Bags) · Phase 2, PHASE3 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02607670 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Topokine Therapeutics, Inc.
Last refreshed: 2 January 2016

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02607670.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing